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ABSTRACT
The DNA methylation epigenetic signature is a key
determinant during development. Rules governing
its establishment and maintenance remain elusive
especially at repetitive sequences, which account
for the majority of methylated CGs. DNA methyla-
tion is altered in a number of diseases including
those linked to mutations in factors that modify chro-
matin. Among them, SMCHD1 (Structural Mainte-
nance of Chromosomes Hinge Domain Containing 1)
has been of major interest following identification of
germline mutations in Facio-Scapulo-Humeral Dys-
trophy (FSHD) and in an unrelated developmental
disorder, Bosma Arhinia Microphthalmia Syndrome
(BAMS). By investigating why germline SMCHD1 mu-
tations lead to these two different diseases, we un-
covered a role for this factor in de novo methylation
at the pluripotent stage. SMCHD1 is required for the
dynamic methylation of the D4Z4 macrosatellite upon
reprogramming but seems dispensable for methy-
lation maintenance. We find that FSHD and BAMS
patient’s cells carrying SMCHD1 mutations are both
permissive for DUX4 expression, a transcription fac-
tor whose regulation has been proposed as the main
trigger for FSHD. These findings open new questions
as to what is the true aetiology for FSHD, the epige-
netic events associated with the disease thus calling
the current model into question and opening new
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perspectives for understanding repetitive DNA se-
quences regulation.
INTRODUCTION
SMCHD1 is a 230 kDa protein grouped in the SMC fam-
ily of chromosomal proteins based on the presence of an
SMC hinge domain (1). However, SMCHD1 is a non-
canonical family member owing to its distinct domain ar-
chitecture, including the presence of an N-terminal GHKL
rather than bipartite ABC-type ATPase domain (2). Addi-
tionally, SMCHD1 exclusively homodimerises via its hinge
domain (2,3), and as a result does not heterodimerise like
other SMC proteins, nor participate in the tripartite ring
complex formed by other cohesins (2). In the mouse, Sm-
chd1 loss of function results in early lethality in female em-
bryos, attributed to derepression of genes on the inactive
X chromosome (1,4,5). SMCHD1 is also involved in the
silencing of repetitive DNA sequences, regulation of clus-
tered imprinted genes, the monoallelically expressed proto-
cadherin genes (5–7) andHox genes (8). SMCHD1 is prefer-
entially loaded ontoH3K9me3-enriched chromatin in asso-
ciation with LRIF1 andHP1 (9,10). In addition, SMCHD1
has been found at telomeres with a direct correlation be-
tween telomere length and SMCHD1 enrichment (11,12)
but its role in the regulation of telomeric chromatin is un-
known.
Recently, heterozygous germline mutations in the SM-
CHD1 gene have been identified in type 2 Facio-Scapulo-
Humeral muscular dystrophy (FSHD2) (13–15). FSHD is
one of themost fascinating syndrome involvingmethylation
changes. This autosomal dominant muscular dystrophy is
ranked as one of the most common myopathies. FSHD is
linked to a complex chromosomal abnormality at the 4q35
subtelomeric locus (16–18). In the majority of patients, a
heterozygous deletion of an integral number of GC-rich
repetitive macrosatellite elements, D4Z4, in the distal re-
gion of the 4q arm is found. This deletion segregates with a
‘permissive’ qA subtelomeric haplotype downstream of this
repetitive array (19,20). In 5% of FSHD cases (FSHD2),
there is no D4Z4 array shortening but a large fraction of
these patients carry a heterozygous mutation in the SM-
CHD1 gene. D4Z4 is extremely GC-rich (70%) (21) and
contains an open reading frame encoding the DUX4 tran-
scription factor (22). In FSHD1 and 2, D4Z4 is hypomethy-
lated (13,23–26) and D4Z4 chromatin relaxation has been
associated with expression of the DUX4 retrogene encoded
by the most distal D4Z4 repeat and adjacent qA haplotype
leading to activation of a cascade of genes which perturbs
skeletal muscle homeostasis (20,27).
More recently, germline SMCHD1 mutations have been
found in patients affected with Bosma Arhinia and Mi-
crophthalmia Syndrome (BAMS), an extremely rare con-
dition characterized by absence of the nose with or with-
out ocular defects. Intriguingly, BAMS patients show no
sign of muscular dystrophy. With <50 patients reported to
date (28,29), arhinia is presumed to result from a specific
defect of the nasal placodes or surrounding neural crest-
derived tissues during embryonic development. In FSHD,
SMCHD1 missense or splice and truncating mutations are
likely loss of function and have been described across the
whole coding sequence while in BAMS, mutations are likely
gain of function and mainly clustered within exons 3 to
13, spanning a GHKL-type ATPase domain and the as-
sociated region immediately C terminal to it (2,9), (28,29).
Although there is some controversy surrounding whether
BAMS missense mutations are loss- or gain of function,
Arhinia has been associated with an increased ATPase ac-
tivity (28–30). Intriguingly, D4Z4 hypomethylation is ob-
served in both diseases indicating that loss or gain of func-
tion mutations are all associated with epigenetic changes at
this macrosatellite but with completely different phenotyp-
ical outcomes (28,29).
In order to investigate the impact of SMCHD1mutations
in FSHD2 and BAMS, we created a collection of human
induced pluripotent stem cells (hiPSCs) from patients with
either diseases. By first analyzing methylation of the D4Z4
macrosatellite involved in FSHD, we showed that D4Z4
methylation is dynamically methylated upon reprogram-
ming. In pluripotent cells, D4Z4methylation is regulated by
SMCHD1. We further show that BAMS and FSHD2 cells
are permissive forDUX4 expression suggesting that besides
SMCHD1’s pleiotropic role in chromatin regulation, SM-
CHD1 BAMS and FSHD mutations also have tissue spe-
cific effects, which remain to be identified.
MATERIALS AND METHODS
Study samples
DNA was extracted from the different types of samples us-
ing the Qiagen DNA prep kit. All individuals have provided
written informed consent for the collection of samples and
subsequent analysis for medical research. The study was
done in accordance with the Declaration of Helsinki. Con-
trols are randomly selected individuals or patient’s relatives,
selected in the same age range and sex representation as
patients. Controls are neither carrier of any genetic muta-
tion nor affected by any constitutive pathology. Samples are
listed in Supplementary Tables S1 and S3.
Cell culture
The human embryonic kidney 293 cells (CRL-1573) and
the male colon carcinoma cell line (CCL-247) were ob-
tained from ATCC. The HCT116 DKO cells were obtained
from Dr. B. Vogelstein Laboratory (1). In HCT116 and 293
cells, SMCHD1 expression was invalidated by transfection
of Zn finger nucleases using CompoZr knockout Zinc Fin-
ger Nucleases (CKOZFN19780, Sigma-Aldrich) targeting
exon 1. After transfection, individual clones were selected
and characterized for homozygous gene deletion. Primary
fibroblasts andHEK293 cells were grown inDMEMwith L-
alanyl-L-glutamine (GlutaMAX™I), D-glucose and sodium
pyruvate (Life technologies). The human colon carcinoma
HCT116 cells were maintained inMcCoy’s medium.Media
were supplemented in with 10% fetal bovine serum (FBS,
Gibco), 1% penicillin/streptomycin (P/S). Cells were grown
at 37◦C, 5% CO2, in a humidified atmosphere.
Human iPSCs clones
All iPSCs clones were derived from primary fibroblasts
(Supplementary Table S1) generated after transfection of
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different vectors by electroporation (pCXCLE-hOCT3/4-
shp53-F (Addgene ref 27077), pCXLE-hSK (Addgene, ref
27078, encoding SOX2 and KLF4), pCXLE-hUL (Ad-
dgene,ref 27080, encoding L-Myc and LIN28). Human iPS
(hiPSCs) colonies were picked 4–6 weeks after transfec-
tion based on their ES cell-like morphology. Colonies were
grown and expanded in mTeSR™1 medium (Stem cells) on
BD Matrigel™ (BD Biosciences, cat. no. 354277) coated
dishes. For each cell line two to three clones were fully char-
acterized using classical procedures (2) such as expression of
pluripotency markers, absence of expression of the repro-
gramming transgenes, phosphatase alkaline staining and
karyotype for checking the absence of chromosomal abnor-
malities. Expression of the Keratin Sulfate antigens Tra1-60
and Tra1-81 and the glycolipid antigens SSEA3 and SSEA4
was verified by flow cytometry.
Sodium bisulfite sequencing
One g of genomic DNAwas denatured for 30 min at 37◦C
in NaOH 0.4 N and incubated overnight in a solution of
3 M sodium bisulfite pH 5 and 10 mM hydroquinone us-
ing previously described protocol (4). Converted DNA was
purified using the Wizard DNA CleanUp kit (Promega)
followingmanufacturer’s recommendation and precipitated
by ethanol precipitation for 5 h at −20◦C. After centrifuga-
tion, DNA pellet was resuspended in 40L of water and
stored at −20◦C until use. In order to amplify both methy-
lated and unmethylated DNAwith the same efficiency, con-
verted DNA was amplified using primer sets designed with
theMethPrimer software (5) avoiding the presence of CpGs
in the primer sequence (Supplementary Table S6). For Ion
Torrent sequencing, primers were modified by 5′ addition
of barcode/adaptors sequences and 3′ addition of BSP se-
quences. Amplification was carried out using the High Fi-
delity Taq polymerase (Roche) according to manufacturer’s
instructions. After initial denaturation at 94◦C for 2 min,
amplification was done after 10 cycles at 94◦C for 20 s, 56◦C
for 30 s, 72◦C for 1 min and 25 cycles at 94◦C for 20 s, 54◦C
for 30 s, and an amplification step of 4 min and 30 s for the
first cycle and an implement of 10 s at each subsequent cycle
followed by a final extension step at 72◦C for 7 min.
PCR products were purified using the Ampure XP kit
(Beckman Coulters) and quantified using the Qubit®
dsDNA High Sensitivity Assay Kit (Thermofisher). An
equimolar mix of all regions and samples/barcodes is pre-
pared. DNA high-throughput sequencing was performed
using Ion PGM Sequencing 400 kit (Life Technologies)
reagents. Ion Sphere Particles (ISP) were loaded onto an
Ion 316R sequencing chip (Life Technologies) and DNA
sequencing was performed with the Ion PGM instrument
at 650 run flows. Raw data were processed using the Ion
Torrent platform-specific pipeline software Torrent Suite
v5.0.4. Sequences were identified by the presence of a 17-
base pair index at the beginning or at the end of the se-
quence. After barcode trimming, data are analyzed us-
ing the Bamtools software (BamTools 2.4.0, https://github.
com/pezmaster31/bamtools, (6)). After sequencing, sense
and antisense sequenceswere assembled in a single sequence
and bam file converted to fastq file. A trimming of each BSP
primers is performed using the fastx barcode splitter.pl
software and the fastq to fasta software (Barcode Split-
ter & FASTX ToolKit, 0.0.13, https://github.com/agordon/
fastx toolkit) is used to prepare data for the BiQ Anal-
yser HiMod software (http://biq-analyzer.bioinf.mpi-inf.
mpg.de) (7). Processed data were exported into the R soft-
ware (version 3.4.2). Aligned sequences with a conversion
rate >90% and a recovery rate >50% were kept for further
analysis. BiQAnalyzer HiMod converts sequencing data by
using ’1’ for a methylated CG, ’0’ for unmethylated and ’x’
in case of misalignment. The percentage of coverage is cal-
culated as the ratio between the numbers of ’x’ divided by
the total number of letters per sequence. Based on the num-
ber of ’1’ or ’0’, three methylation score are calculated, (i)
the CpG methylation score corresponds to the percentage
of methylation for each CpG in the reference sequence cal-
culated as the ratio of methylated CpGs on the number of
CpGs aligned to the reference sequence, (ii) the sequence
methylation score, corresponds to the average methylation
level of each sequence calculated as the ratio of methylated
CpG of all aligned CpG for a given sequence and (iii) the
global methylation score corresponds to the global level of
methylation for each biological sample in a given region cal-
culated as the ratio of methylated CpG with the number
of aligned CpG for all sequences and CpG positions for a
given biological sample. Graphics representations were per-
formed using barplot, boxplot and hist functions.
RNA extraction and quality control
Total RNA was extracted using the RNAeasy kit (Qiagen)
following manufacturer’s instructions. Quality, quantifica-
tion and sizing of total RNA was evaluated using the RNA
6000 Pico assay (Agilent Technologies Ref. 5067-1513) on
an Agilent 2100 Bioanalyzer system.
Quantitative RT-PCR
Reverse transcription of 1 g of total RNA was performed
using the Superscript II kit and oligo dT following manu-
facturer’s instructions at 42◦C for 50min followed by inacti-
vation at 70◦C for 15 min (Life Technologies). Primers were
designed using Primer Blast and Primer3 (Supplementary
Table S7). Real-time PCRamplificationwas performed on a
LightCycler 480 (Roche) using the SYBR greenmaster mix.
All PCRwere performed using a standardized protocol and
data were analyzed with the Lightcycler 480 software ver-
sion 1.5.0.39 (Roche). Primer efficiency was determined by
absolute quantification using a standard curve. For each
sample, fold-change was obtained by comparative quan-
tification and normalization to expression of the HPRT,
GAPDH and PPIA (DUX4 and DUX4 target genes) or
36B4 (characterization of hiPSCs) housekeeping genes used
as standard. Data are expressed as means ± SEM.
RT-PCR for DUX4
One g of total RNA was used for first strand cDNA syn-
thesis using SuperScript IV reverse transcriptase and a mix-
ture of oligo dT and hexanucleotide primers. Primary PCR
reactions were performed with Taq DNA polymerase (Eu-
romedex) using 7% of the first strand reaction as template
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in a total reaction volume of 30 l. Nested PCR reactions
were performed on 1 l of the primary reaction. In order to
discard any risk of contamination by genomic DNA, each
RNA sample was treated withDNAseI and PCR amplifica-
tion was performed on RNA samples incubated in the ab-
sence of reverse transcriptase (RT–) or without addition of
cDNA. In all cases, amplification products were only ob-
served when RNA samples were reverse-transcribed. For
DUX4-fl detection the following primers were used as de-
scribed (8) (Supplementary Table S7). PCR products were
examined on 3% Molecular Biology Grade Agarose gels
stained with ethidium bromide. All PCR products were
sequenced and compared to Genbank accession number
KX467569 and KX467570.
3′ UTR RACE
For the 3′ UTR RACE, reverse transcription
was realized with an oligo-dT adapter primer:
(GCTGTCAACGATACGCTACGTAACGGCATG
ACAGTGTTTTTTTTTTTTTTTTTTTTTTTT) as de-
scribed (9). PCRs were performed in a final volume of 15 l
with 1 l of RT product, 3 l of reverse primer at 20 M
and 1 l of primer at 20 M, 7.5 l 2× PCR MasterMix
(ThermoScientific). The PCRcycling conditions were 94◦C
for 5 min, followed by 5 cycles at 94◦C for 20 s and 72◦C
for 50 s, then 5 cycles at 94◦C for 20 s and 70◦C for 30 s
and 72◦C for 20 s and 25 cycles at 94◦C for 20 s and 68◦C
for 20 s and 72◦C for 30 s, followed by a final extension at
72◦C for 7 min. The nested PCRs were realized in a final
volume of 15 l with 1 l of primary PCR product, 1 l
of reverse and/or forward primers 20 M, 7.5 l 2×
PCR MasterMix (Thermo Scientific).The PCR cycling
conditions were 94◦C for 5 min, followed by 35 cycles
at 94◦C for 20 s and 60◦C for 20 s and 72◦C for 30 s,
followed by a final extension at 72◦C for 7 min. Nested
PCR products were purified using a NucleoSpin Gel and
PCRClean-Up column (Macherey-Nagel).Fragments were
cloned into TOPO-TA vector with a TOPO-TA Cloning
kit (LifeTechnologies).Cleavage sites were determined by
Sanger sequencing of at least 10 Individual clones.
Chromatin immunoprecipitation (ChIP)
Between 10–20 × 106 cells were cross-linked with 1%
formaldehyde for 10 min at room temperature then for 40
min at 4◦C. Cross linking reaction was stopped by addition
of glycine (final concentration 0.125M). Cells were washed
twice in ice-cold PBS, harvested and incubated for 10min in
1 ml ice-cold lysis buffer (5 mMPIPES pH 8.0, 85 mMKCl,
0.5%NP40, protease inhibitors). Nuclei were extractedwith
using a dounce homogeneizer and collected by centrifuga-
tion at 5000 rpm for 5 min at 4◦C. Nuclei were then resus-
pended in a 50 mM Tris–HCl pH 8, 10 mM EDTA, 1%
EDTA solution. Chromatin was sonicated using a Biorup-
tor instrument (Diagenode) to an average length of 400–
600 bp. After centrifugation for 10 min at 14 000 rpm, su-
pernatants were collected and diluted 10 times in a dilu-
tion buffer (16.7 mMTris–HCl pH 8, 167 mMNaCl, 0.01%
SDS, 1.1% Triton X-100, 1.2 mMEDTA). Pre-clearing was
performed using a mixture of Protein A and G sepharose
(50:50, Sigma) for 1 h at 4◦C. ChIP-ready chromatin was
pulled down with either anti-H3 (Milipore, 04–928), anti-
H3K9me3 (Millipore, 07-442) or anti-SMCHD1 (Abcam,
ab31865) overnight under rotation at 4◦C. Chromatin was
then incubated with magnetic beads coupled with protein A
or G agarose (Milipore, 16-661; 16-662) for 1 h at 4◦C un-
der rotation. Beads were washed under rotation for 5 min
in different buffers: low salt wash buffer (TE 2×, 150 mM
NaCl, 1% Triton X-100, 0.1% SDS), high salt wash buffer
(TE 2×, 500 mM NaCl, 1% Triton X-100, 0.1% SDS),
LiCl wash buffer (TE 1×, 0,25 mM LiCl, 1% NP40, 1%
sodium deoxycholate), TE 1×. Immune complexes were
eluted by addition of 500 l elution buffer (1% SDS, 0.1 M
NaHCO3). Cross-links were reversed by addition of 20 l
of NaCl 5 M for 4 h at 65◦C. DNA samples were then
recovered by phenol/chloroform extraction, ethanol pre-
cipitation and resuspended in water. Enrichment of the
immunoprecipitated fraction/input was quantified by real
time qPCR. Primers were designed using Primer Blast and
Primer3 (Supplementary Table S8).
Digital droplet PCR
For ChIP quantification, chromatin immunoprecipitated
using anti-histone H3 antibodies (positive control) and 1%
input were used as controls for ddPCR analysis. Briefly, we
used 1 l of ChIP samples in 20 l of 0.1 mM primers
and 10 l of either 2× ddPCR Supermix (no dUTP) for
probes or 2× ddPCR Evagreen supermix. After droplets
generation, samples were transferred into a 96-well plate for
PCR amplification. The plate was processed with a ddPCR
reader, using appropriate settings depending on the reaction
mixture (Evagreen or Mix for probes). Only wells with >13
000 droplets counted were kept for analysis. Results are nor-
malized to input and a unique intergenic chromosome 5 lo-
cus. PCR primers were tested on genomic DNA to verify
specificity and efficiency.
Detection of telomerase activity in hiPSCs was performed
as described (10). Approximately 10,000 hiPSCs cells were
lyzed in 40 l of NP-40 buffer (10 mM Tris–HCl, pH 8.0,
1 mM MgCl2, 1 mM EDTA, 1% (vol/vol) NP-40, 0.25
mM sodium deoxycholate, 10% (vol/vol) glycerol, 150 mM
NaCl, 5 mM -mercaptoethanol; 0.1 mM AEBSF (4-(2-
aminoethyl)benzenesulfonyl fluoride hydrochloride). One
microliter of this lysate was added to a 50 l extension re-
action containing 1× TRAP reaction buffer (10× concen-
tration: 200 mM Tris–HCl, pH 8.3, 15 mM MgCl2), 0.4
mg/ml BSA, TS telomerase extension substrate (HPLC pu-
rified, 200 nM; 5′-AATCCGTCGAGCAGAGTT), dNTPs
(2.5 mM each) and incubated for 40 min at 25◦C fol-
lowed by telomerase inactivation at 95◦C for 5 min, then
held at 4◦C. The ddPCR reaction contained 1× EvaGreen
ddPCR Supermix v2.0 (Bio-Rad, Hercules, CA, USA), 50
nM TS primer, 50 nM ACX primer, 50 cell equivalents or
less of extension product and dH2O to 20 l per sample.
Droplets were produced in the droplet generator accord-
ing to the manufacturer’s instructions (Bio-Rad, Hercules,
CA,USA), the emulsions transferred to a 96-well PCRplate
for the PCR reaction. PCR reaction was performed as de-
scribed (10) with a ramp rate of 2.5◦C/s between all steps.
On average 17 000 droplets were analyzed per 20 l PCR.
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Statistical analysis
For DNA methylation, statistical analyses were done with
R (version 3.4.2) and RStudio softwares, dplyr library and
ComplexHeatmap library from Bioconductor (version 3.6).
DNA methylation levels were compared using a Wilcoxon
non-parametric test (wilcox.test function). The significance
threshold ( = 0.05) was corrected for multiple compar-
isons using the Bonferroni method for False Discovery Rate
(FDR) determination. Only values showing a significant
correlation with a P-value <0.05 are presented. Heatmaps
and Manhattan distance calculation were used to simulta-
neously visualize clusters of samples and global methyla-
tion of the different sequences. Clusters of CpGbyCpGdif-
ferentially methylated were determined using an Euclidean
distance calculation. For each sample, we used the Mix-
tools version 1.1.0 package in R that estimates the sampling
distribution using a random sampling method and confi-
dence intervals calculation. Bootstrap was used to deter-
mine a confidence interval for the ratio of methylated CG
divided by the number of CG analyzed for each sample by
constructing an interval centered at a point estimate with a
margin of error equal to twice the standard error.
RESULTS
D4Z4 is remethylated upon reprogramming in cells from
FSHD1 patients
Using sodiumbisulfitemodification (31) coupledwith deep-
sequencing (Roche et al. Submitted), we investigated the
methylation profile of the D4Z4 macrosatellite in primary
fibroblasts and derived hiPSCs clones fromFSHD1patients
carrying a shortened D4Z4 array and healthy donors (Sup-
plementary Table S1). For each sample, two to three hiPSC
clones were isolated and amplified for at least 20 passages
to erase donor cell memory, which is usually maintained at
early passages (32).We selected pluripotent clones by check-
ing OCT4, NANOG and SOX2 expression (Supplementary
Figure S1), verifying extinction of the episomal genes and
presence of a normal karyotype (not shown) and finally en-
suring that these clones had a differentiation potential (Sup-
plementary Figure S2).
In primary fibroblasts from FSHD1 patients, D4Z4 is hy-
pomethylated with most methylation changes occurring at
the DR1 and 5P regions, located upstream of the DUX4
coding sequence while methylation of theMID (DUX4 pro-
moter) and 3P (end of DUX4 exon 1 coding sequence) are
not modulated (Figure 1A), as observed in blood (15,33).
In control hiPSC clones, D4Z4 methylation is slightly in-
creased compared to the corresponding fibroblasts with
an average increase of methylation of 8.4% for DR1 and
11% for 5P between fibroblasts and pluripotent cells (Fig-
ure 1A, Supplementary Table S2), a trend of hyperme-
thylation described for other subtelomeric regions (34,35).
This increased level of methylation is significantly more
pronounced in FSHD1 hiPSCs with an average increase
of 27.9% for DR1 (P value < 0.04) and 29.2% for 5P
(P value < 0.036) between fibroblasts and correspond-
ing pluripotent cells (Figure 1A, Supplementary Table S2).
When we compared the global methylation level and dis-
tribution at the individual CpGs level between clones from
the same donor, we did not observe any striking difference.
Altogether, this indicates that upon reprogramming, D4Z4
methylation level is systematically increased in cells derived
from FSHD1 patients carrying a shortened D4Z4 array.
This observation was corroborated by analyzing fibrob-
lasts and hiPSC clones from a patient carrying a mosaic
of short and long D4Z4 alleles (25% of cells carrying a
short D4Z4 array of two units in fibroblasts) (Figure 1B,
Supplementary Table S2). As observed in FSHD1 patients,
D4Z4 methylation level is higher in hiPSC clones compared
to fibroblasts (DR1: 38.6% and 5P: 47.7%). Methylation
level, in this mosaic patient is similar between clones but
more importantly between the two hiPSC clones carrying
the short D4Z4 array (two repeats; mean methylation level
at DR1: 76.8% ± 4.75%; 5P: 76% ± 4.14%) and the two
clones carrying the long array (11 repeats; mean methyla-
tion level at DR1: 84.1%± 4.89%, 5P: 82.8%± 2.52%) (Fig-
ure 1B, SupplementaryTable S2). Importantly, by analyzing
the distribution of methylated DNA molecules in this mo-
saic patient (Supplementary Figure S3A; B), we observed
similar distributions for hypo- (number of molecules with
a methylation level <25%) or highly methylated (number
of molecules with a methylation level >60%) molecules be-
tween both types of clones (short D4Z4 array correspond-
ing to an FSHD allele or long array, healthy allele).
Taken together, these results reveal a higher level of
methylation in pluripotent stem cells compared to the
fibroblasts-of-origin. This indicates that D4Z4 remethyla-
tion occurs after cell reprogramming and suggests a dy-
namicmethylation of the repeat. Furthermore, as evidenced
by comparing somatic and stem cells from patients with a
shortened D4Z4 array (FSHD1) or from a mosaic patient,
D4Z4 remethylation shows that the level of methylation of
the macrosatellite does not depend on the residual number
repeats. The analysis of different clones per patient and dif-
ferent patients excludes clonal variability as an explanation
of our findings.
High D4Z4 methylation is a feature of pluripotency
To further investigate whether remethylation in hiPSCs is
dependent on reprogramming or a feature of pluripotency,
we analyzed D4Z4 methylation in human Embryonic Stem
Cells (hESCs) from three healthy donors or three donors
carrying a short D4Z4 array (FSHD1) (Figure 2, Supple-
mentary Table S1). As observed in hiPSCs, D4Z4 methy-
lation is not significantly different between healthy donors
andFSHD1hESCs. In the two groups of samples, theD4Z4
repeat is highly methylated for the different regions ana-
lyzed without any significant difference between hESCs and
hiPSCs (Figure 2, Supplementary Figure S4A, Supplemen-
tary Table S2). Altogether this indicates thatD4Z4 ismethy-
lated to a level>75% of methylated CGs in pluripotent cells
(either induced or embryonic), independently of the number
of copies of the macrosatellite. Overall these results show-
ing no difference between FSHD1 and control hiPSCs and
hESCs indicate that D4Z4 methylation depends on stem-
ness rather than on the number of residual copies.
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Figure 1. Methylation of the D4Z4 macrosatellite increases upon reprogramming in FSHD1 cells. (A) DNA methylation was determined after sodium
bisulfite modification for four subdomains across D4Z4 by PCR amplification and high throughput DNA sequencing. DR1 and 5P are located upstream
of theDUX4 coding sequence, MID corresponds to theDUX4 promoter and 3P, to the end ofDUX4 exon 1 encoding the protein. For each sequence, dots
represent individual CpG. For the different types of samples (control or FSHD1 fibroblasts; controls or FSHD1 hiPSCs), we plotted the mean methylation
level of each CpG for the four D4Z4 subdomains. Histogram bars represent the average of methylated (black) or unmethylated (white) CpG for each
position in DNA from primary fibroblasts from 8 controls (row 1, mean methylation level for DR1: 71.4% ± 8.8, mean methylation level for 5P, 73.1%
± 13.1) and four FSHD1 (row 2, mean methylation level for DR1: 39.9% ± 4.4, mean methylation level for 5P, 40.5% ± 3). For hiPSCs derived from
control (row 3, DR1: 79.8% ± 16.6 and 5P: 84.1% ± 7.4) and FSHD1 fibroblasts (row 4, DR1: 67.8% ± 23.4 and 5P: 69.7% ± 11.1), the average mean
methylation level of each CG is represented as above. For each histogram, the mean methylation level in control fibroblasts is indicated by a black line, or
a grey line in FSHD1 fibroblasts. In hiPSCs, the mean methylation level is indicated by a dashed black line for conrols or a dashed grey line for FSHD1
cells. Methylation level is significantly increased in FSHD1 hiPSCs for DR1 (P value <0.04) and for 5P (P value <0.036) compared to fibroblasts. (B) We
analyzed the D4Z4 methylation pattern in fibroblasts from a mosaic patient clinically affected with FSHD and carrying a short 2 D4Z4 units repeat in 25%
of cells and a long 11 D4Z4 units repeat in 75% of cells. DNA methylation was also analyzed in two hiPSCs clones carrying the 11 D4Z4 units repeat and
two hiPSCs clones carrying the 2 D4Z4 units repeat derived from this patient’s fibroblasts. Mean methylation level was plotted as detailed above. Values
are given in the Supplementary Table S2. In fibroblasts from this mosaic patient, the mean methylation level is indicated by a gray line. The black lines
correspond to the mean methylation levels in control fibroblasts. In hiPSCs, the dashed black line corresponds to the mean methylation level in control
hiPSCs. The methylation level in hiPSCs is not significantly different between the different clones or compared to the controls.
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Figure 2. D4Z4 methylation profiles in control and FSHD1 embryonic stem cells. We compared the methylation profile of the four different D4Z4 sub-
domains (DR1, 5P, MID and 3P) in three different human embryonic stem cells (hESCs) from healthy donors and three different donors carrying a short
D4Z4 array (FSHD1). Each sample is represented individually. Histogram bars represent the percentage of methylated (black) or unmethylated (white)
CpG for each position and each individual sample.
D4Z4 remethylation is reduced in cells carrying mutations in
SMCHD1
The majority of type 2 FSHD patients displaying a marked
D4Z4 hypomethylation carry a mutation in the SMCHD1
gene. D4Z4 hypomethylation and SMCHD1 mutations
have also been found in BAMS (28,29). In FSHD2, SM-
CHD1 mutations are associated with a loss of function of
the protein while a gain of ATPase activity is suggested
in most BAMS cases. These results strongly suggest that
D4Z4 hypomethylation is not specific to FSHD but likely
controlled by dosage of the functional homodimeric com-
plex formed by this chromatin-associated factor (30). To
test this hypothesis and evaluate the influence of SMCHD1
gene dosage on D4Z4 methylation, we first analyzed its
methylation profile in blood DNA from patients carrying
a deletion of the 18p11.32 region encompassing the SM-
CHD1 gene and phenocopying the FSHD2 loss-of-function
situation (Supplementary Figure S5A; Supplementary Ta-
ble S3). As in BAMS (29), we observed a marked de-
crease in D4Z4 methylation in the four 18p deletion sam-
ples analyzed (DR1: 22.7% of methylated CG ± 9.6; 5P:
51.7% ± 5.4) compared to controls (DR1: 71.4% of methy-
lated CG; 5P: 75%, Roche et al. submitted). Interestingly,
D4Z4 methylation is not increased in individuals carrying
an 18p11.32 duplication and three SMCHD1 copies (Sup-
plementary Figure S5B; Supplementary Table S2). Thus,
D4Z4 methylation is sensitive to the decrease in SMCHD1
gene dosage but not increased by additional SMCHD1 gene
copies.
To investigate the role of SMCHD1 in the regulation of
D4Z4 methylation in stem cells, we assessed D4Z4 methy-
lation in fibroblasts from FSHD2 and BAMS patients and
their corresponding hiPSCs clones by sodium bisulfite se-
quencing (Figure 3, Supplementary Figure S6). For DR1,
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Figure 3. D4Z4 remethylation is impaired by mutation in SMCHD1. (A) Schematic representation of the SMCHD1 protein and position of mutations in
BAMS (cyan) or FSHD2 patients (red). BAMS-1 (E136G) and BAMS-2 (S135C) carry a missense mutation in the ATPase domain reported as a gain of
function. BAMS-9 carries a missense mutation in the C-terminal region of the extended GHKL-like ATPase domain (D420V). FSHD2 patient #14586
also carries a mutation in the ATPase domain (Q193P) while FSHD2-11440 and FSHD2-11491 carry a truncating mutation (p.S754* and p.V1826Gfs*19
respectively). (B)DNAmethylationwas determined after sodiumbisulfitemodification for 4 regions acrossD4Z4 (DR1, 5P,MID, 3P) by PCRamplification
and high throughput DNA sequencing. For each sequence, dots represent individual CpGs. The mean methylation level of each CpG was plotted for the
4 D4Z4 subdomains. Histogram bars represent the average of methylated (black) or unmethylated (white) CpG for each position in DNA from fibroblasts
(rows 1; 2) from FSHD2 patients (n = 3) and patients with BAMS (n = 3) and corresponding hiPSCs clones (rows 3; 4). For each histogram, the mean
methylation level in control fibroblasts is indicated by the black line. In hiPSCs, the mean methylation level is indicated by a dashed black line for controls.
(C) Boxplot representation of the mean methylation level for the DR1 and 5P differentially methylated sequences in primary fibroblasts and hiPSCs from
control donors, FSHD1, FSHD2 and BAMS patients. Significant differences are indicated by brackets with the corresponding pvalues determined using
a Kruskal–Wallis non parametric test.
D4Z4 methylation only slightly increases in FSHD2 hiPSC
clones (n = 4; DR1: 28% of methylated CGs ± 12.7 com-
pared to 15.7% of methylated CGs ± 14.1 in fibroblasts)
compared to BAMS patients (n = 3; DR1: 46.2% ± 6.3 in
hiPSCs compared to 21.3% of methylated CGs ± 11.7 in
fibroblasts, P value = 0.05) (Figure 3, Supplementary Ta-
ble S2). We concluded from these results that SMCHD1
might be implicated in the deposition ofmethylmarks at the
pluripotent stage. Differences between FSHD2 and BAMS
cells in the dynamics of D4Z4methylation also suggest that,
as observed for the ATPase activity, the type of mutations
impacts the regulation of D4Z4 methylation differently.
Methylation changes linked to mutations in SMCHD1 only
occur for a specific subset of repetitive sequences
To test whether methylation differences observed in the dif-
ferent types of samples are specific to D4Z4 or concern
other types of repeats, we applied the same methodology
to analyze the methylation level of other types of repetitive
elements. We selected primers for dispersed repeats such as
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interspersed AluI or LINEs considered as surrogate mark-
ers of the global epigenetic status, the RS447 macrosatel-
lite or TAR1 subtelomeric sequences. In hiPSCs or hESCs
from controls or FSHD1 patients, we did not see any differ-
ence in the level of methylation for the AluI, LINE-1, and
RS447 repetitive elements (Supplementary Figures S4; 7,
Supplementary Table S4). Regarding the TAR1 sequence,
methylation is decreased in fibroblasts from FSHD1 pa-
tients but highly variable between individuals (46.7%± 27.2
compared to 67.11%± 11.2 in controls). We made the same
observations in hiPSCs from FSHD2 patients. Thus, TAR1
methylation is not sensitive to heterozygous SMCHD1mu-
tations but more variable between samples, as observed for
other subtelomeric sequences (34,35).
We concluded that upon reprogramming, remethylation
of theD4Z4 repeat is not linked to its subtelomeric position.
Specific differences in D4Z4 methylation between FSHD1
and SMCHD1-mutated cells strengthen the hypothesis of a
role for this protein in D4Z4 regulation.
Imprinting and X inactivation are not altered in FSHD2 and
BAMS cells
Based on inactivation studies in the mouse, Smchd1 has
been involved in X inactivation (1) and more recently, in
the regulation of imprinted genes and monoallelically ex-
pressed loci (6,7,36). To test whether methylation of some
of these loci is affected by SMCHD1 mutations found in
FSHD2 and BAMS patients, we first analyzed the methyla-
tion status of the IGF2/H19 differentiallymethylated region
(DMR) corresponding to the imprinting control region of
this locus in the different cell types (Figure 4A, Supple-
mentary Table S5). By plotting the mean methylation level
for the different categories of samples we did not observe
any difference between the frequency of methylated versus
unmethylated alleles in the different conditions. This indi-
cates that heterozygous SMCHD1mutations in BAMS and
FSHD2 patients do notmodify the regulation of imprinting
of this locus in primary somatic cells or after reprogram-
ming in pluripotent cells.
Neither FSHD2 nor BAMS have been linked to changes
or skewedX inactivation. Nonetheless, we tested for X inac-
tivation changes in female cells with SMCHD1 mutations.
To this aim, we first used 3DDNAFISH and hybridization
with a whole X painting probe to determine X chromosome
volume in fibroblasts and hiPSCs. As expected, themajority
of female cells had two signals corresponding to theXprobe
while only one signal was detectable inmale cells attesting to
the specificity of the probe (Supplementary Figure S8). In
the different contexts (controls, FSHD2, BAMS), we cal-
culated the volume of X signals in male fibroblasts (6.035
m3) and hiPSCs (3.49 m3) and compared these values
used as control of active X to the volumes measured in the
other samples (Supplementary Figure S8). In female cells
from controls, FSHD2 or BAMS, the two X chromosomes
were analyzed separately (red and black dots). Volumes are
equivalent to controls in FSHD2 hiPSCs and BAMS cells.
We observed a broad distribution of volumes in female con-
trol hiPSCs and FSHD2 primary fibroblasts. This indicates
that chromosome X volume is not modified in female cells
with mutations in SMCHD1.
We next sought to determine the methylation profile of
the X-linked DXZ4 macrosatellite repeat in the different
contexts (Figure 4B, C; Supplementary Table S5). This el-
ement is a GC-rich tandem repeat of between 12 and 120
uninterrupted 3 kb units located on Xq23. Males are hem-
izygous for DXZ4 while females carry several copies of this
macrosatellite on the active (Xa) and inactive (Xi) chromo-
somes (37). In males and on the female Xa from somatic
cells or male hESCs, DXZ4 is heavily methylated but hy-
pomethylated on the Xi in female cells (38).
To test whether SMCHD1 mutations influence the
methylation profile of this macrosatellite, we analyzed
DXZ4 methylation in the different contexts after bisulfite
modification and deep sequencing (Figure 4B). As done ear-
lier, we analyzed the distribution of hypo (meanmethylation
<25%) or hypermethylated sequences in male cells. We ob-
served amain peak of methylation with a meanmethylation
level of 90–100% methylated CG per DNAmolecule (green
curves). This indicates that in male cells, the large major-
ity of DXZ4 molecules are highly methylated in all samples
tested, regardless of SMCHD1 status. As expected from the
difference of methylation reported for the Xa and Xi, fe-
male cells display two peaks of methylation, with molecules
harboring a low methylation level (0–10% of methylated
CGs, red curves) likely corresponding to the hypomethy-
lated Xi and molecules with a high methylation level (90–
100%, green curves) corresponding to the Xa (Figure 4C).
We observed the same distribution in fibroblasts from fe-
male FSHD2 or BAMS patients indicating that SMCHD1
mutations do not affect the methylation of this macrosatel-
lite. By comparing the mean methylation level in the dif-
ferent samples, we observed a high methylation level in
male control and BAMS fibroblasts. Surprisingly the level
ofmethylation is decreased in fibroblasts frommale FSHD1
and FSHD2 patients, regardless of the SMCHD1 status
(Figure 6C). Despite this decreased methylation in male
FSHD cells, we observed no notable difference between fi-
broblasts and hiPSCs indicating that DXZ4 methylation is
maintained after reprogramming in the different subsets of
samples.
In female cells, where only the Xa is methylated, we
observed no difference in patients’ cells, with an average
50% of methylated molecules as expected for the Xa/Xi
ratio (Figure 4C). Altogether, these results suggest that in
FSHD2 and BAMS patients, SMCHD1 mutations do not
affect DXZ4 methylation in somatic cells or in hiPSCs after
reprogramming.
D4Z4 remethylation coincides with acquisition of pluripo-
tency upon reprogramming
To evaluate the role of SMCHD1 in D4Z4 remethylation
upon reprogramming, we analyzed the kinetics of D4Z4
methylation at different time points after transfection of the
reprogramming cocktail in controls (n = 2), FSHD1 (n =
2), FSHD2 (n = 2; 11491: p.V1826Gfs*, 14586: p.Q193P)
and BAMS (n= 2; BAMS1: p. E136G, BAMS9: p. D420V)
primary fibroblasts. Cells were collected at different time
points and processed as detailed (Figure 5A). Given the lim-
ited amount of DNA available at each step, we focused our
analyses on theDR1 and 5P sequences wheremost remethy-
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Figure 4. FSHD2- or BAMS-linked SMCHD1 mutations do not alter H19 imprinting or X chromosome conformation and methylation. (A) We plotted
the mean methylation level for the H19 imprinted locus differentially methylated region (DMR) after bisulfite sequencing. Values are not significantly
different between samples with approximately the same amount of methylated or unmethylated molecules in the different samples. This indicates that
mutations in SMCHD1 do not modify imprinting of this locus in primary cells or after reprogramming. (B) Representative distribution of the frequency of
sequences relative to their level of methylation for the DXZ4 macrosatellite element in the different contexts (control male, control female, female FSHD2,
female BAMS). Histogram bars represent the frequency of methylated molecules from low (0–10%) to high (90–100%) methylation. The mean methylation
level for each group is determined as the area under the curve. Green curves, high methylation level; red curves, low methylation level. (C) We plotted the
mean methylation level for the DXZ4 macrosatellite element in female (left graph) or male (right graph) fibroblasts and hiPSCs.
lation occurs. Methylation of the DR1 and 5P D4Z4 re-
gions is decreased in FSHD1, FSHD2 and BAMS fibrob-
lasts compared to controls (Figure 5B). Upon reprogram-
ming, we observed a progressive increase in the level of
methylation in hiPSCs clones fromFSHD1 patients (Figure
5B, C) with methylation reaching a level significantly differ-
ent from the donor cells (P value < 0.05) and almost iden-
tical to the controls (Figure 5B, C). This increased methy-
lation appears after reactivation of the endogenous OCT4
pluripotency marker (Figure 5D) and of the telomerase
(Figure 5E) suggesting that it is associated with cell stem-
ness. D4Z4 methylation remains low over time in FSHD2
cells (Figure 3B). Interestingly, methylation raises after the
first passage in BAMS cells and remains higher in these cells
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Figure 5. D4Z4 remethylation correlates with expression of pluripotencymarkers and telomerase reactivation. (A) Timeline of the analysis of D4Z4methy-
lation dynamics upon reprogramming. (B) DNAmethylation was analyzed in primary fibroblasts at low passage prior to reprogramming. Reprogramming
was performed by electroporation of vectors encoding the different reprogramming factors. Six days after, cells are collected and plated on MEFs. A
fraction of them were kept for methylation analysis (P0). Clones emerge between 2 and 3 weeks on the layer of feeders. For each sample, 10 clones were
randomly chosen and isolated. For each clone, a fraction was kept for amplification. DNA and RNA extraction was done on the remaining cells pellet.
(C, D) DNA methylation was analyzed after sodium bisulfite modification and deep-sequencing for the DR1 (C) and 5P (D) regions at different time
points (after plating on MEFs (P0), first (P1), fifth (P5) or tenth (P10) passage) in ten clones/sample from two controls (white bars), two FSHD1 (black
bars), two FSHD2 (dark gray) and two BAMS (light grey) patients. For each time point, the average methylation level ± S.D. is reported. Data sets were
compared with the Wilcoxon non-parametric test and brackets identify significantly different groups based on post hocDunn comparison and Bonferroni
correction (** P< 0.001) between P0 and P10. (D) To monitor reprogramming, expression of theOCT4 pluripotency marker was determined by RT-qPCR
at the different time points. (E) Telomerase reactivation was monitored by ddTRAP at different time points using previously described conditions (56). The
threshold between positive and negative droplets was determined by including controls such as a no-template lysis buffer control (CT−), a control where
no primers were present but lysate was added to the ddPCR (Mock) and a control in the absence of enzyme for primer extension (Ext). The U87 cell line
was used as positive control (CT+). Once the threshold (i.e. separation of positive droplets and negative droplets) was determined, the output was given
in molecules of extension products per microliter of ddPCR reaction. We defined telomerase activity as the number of extended TS molecules counted by
ddPCR and expressed in molecules per l. The measured telomerase activity was then converted to total product generated. The telomerase activity was
normalized to a per-cell equivalent basis by dividing total product generated by the number of cell equivalents input into the assay. Telomerase activity is
detectable at passage 2, stable between passages two and six and increased between passages 8 and 10.
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compared to FSHD2 cells mutated for SMCHD1 but never
reaches the level of controls or FSHD1 cells.
Altogether, our results strongly support a dynamic D4Z4
remethylation upon reprogramming that follows acquisi-
tion of pluripotency. In FSHD1 cells, D4Z4 remethylation
to a level similar to control cells and human ESCs indicate
that D4Z4 methylation level does not reflect the number of
residual copies of the macrosatellite. Weak remethylation in
FSHD2 cells also reveals a role for SMCHD1 in the distri-
bution of methylated CGs at the pluripotency stage. Unlike
mutations in FSHD2, BAMS mutations do not inhibit this
remethylation suggesting that the increased ATPase activ-
ity linked to the SMCHD1 gain of function mutations in
BAMS cells does not favor D4Z4 remethylation or that the
ATPase activity is moderately required for D4Z4 methyla-
tion.
SMCHD1 binds to the proximal part of the D4Z4 repeat
Based on the impact of SMCHD1 mutations on the depo-
sition of methyl marks in stem cells, we tested the role of
SMCHD1onD4Z4 regulation in pluripotent cells from two
BAMS and two FSHD2 patients (Figure 6A). One BAMS
patient carries a mutation in the ATPase domain (E136G,
core ATPase adjacent motif I) that causes an increased en-
zymatic activity (29,30) suggesting that the mutation acts
as a gain of function. The second BAMS patient carries a
mutation in the C-terminal portion of the extended GHKL
ATPase domain (D420V) where using the same ATPase as-
say in recombinant protein we have not found an effect on
the enzymatic ATPase activity (29). One of the FSHD2 pa-
tients carries a stop mutation in the hinge domain (11491,
p.V1826Gfs*19), likely associated with haploinsufficiency.
The second patient carries a missense mutation in the AT-
Pase domain (14856, Q193P, core ATPase adjacent motif
II), not reported in BAMS. To assess the impact of this mu-
tation in the catalytic activity of the SMCHD1 protein, we
first tested in vitro the SMCHD1 ATPase activity using re-
combinant proteins in previously described conditions (30).
By measuring ADP production after addition of different
concentrations of ATP and different quantities of recombi-
nant protein (WT or mutated), we observed the absence of
ATP hydrolysis and ADP production for the Q193P muta-
tion compared to the control. Proline confers protein rigid-
ity likely affecting protein folding and in turn protein func-
tion and replacement of a Glutamine by a Proline residue
abrogates SMCHD1 catalytic activity (Figure 6B).
We next performed chromatin binding analyses by chro-
matin immunoprecipitation assay and digital droplet PCR
quantification for the DR1, 5P, MID and 3P regions (Fig-
ure 6C). We observed a significantly stronger association of
SMCHD1 to D4Z4 in FSHD2 cells from the Q193P patient
compared to FSHD1 and control cells. Interestingly, bind-
ing to D4Z4 is also increased in BAMS cells. Thus, despite
a low level of D4Z4 methylation in these samples (Supple-
mentary Figure S6) and mutations in the ATPase domain,
SMCHD1 is able to bind to the repeat indicating that SM-
CHD1 binding is not dependent on D4Z4 methylation level
and that SMCHD1 can be recruited to hypomethylated re-
peats (Figure 6C) with a higher affinity for mutations occur-
ring in theATPase domain. The increase binding in FSHD2
and BAMS cells further suggests that the ATPase domain
might be required for loading/release of the protein to/from
DNA (Figure 6C).
Both FSHD and BAMS pluripotent cells are permissive for
DUX4 expression and express the DUX4-fl pathogenic tran-
script
SMCHD1 loss-of-function, D4Z4 hypomethylation and
chromatin relaxation followed by activation of the DUX4
retrogene encoded by the last D4Z4 repeat and adjacent
pLAM sequence is thought to be the driver mechanism in
FSHD2 (Figure 6D). TheDUX4 open reading frame is fully
contained within the first exon encoded by D4Z4 whereas
exons 2 and 3 corresponding to the DUX4 3′ untranslated
region (3′ UTR) are encoded by the pLAM adjacent re-
gion (39). The main polyadenylation site (PAS) required
for transcript stabilization and protein production is con-
tained within exon 3 (Figure 6D). Additional alternative
polyadenylation sites have also been identified distal to the
last repeat suggesting alternative site usage (39). Only the
long DUX4 transcript (DUX4-fl) has been associated with
FSHD.
Given the methylation changes in FSHD and BAMS, we
tested the presence of the pathogenic DUX4-fl transcript
in different hiPSC clones (controls, FSHD1, FSHD2 and
BAMS patients) using previously described conditions and
quantitative PCR (40). We observed the absence of DUX4-
fl transcript in hiPSCs from healthy donors (Figure 6E,
F). DUX4-fl is expressed in FSHD1 cells despite the high
methylation level (Figure 6E, F) including in clones derived
from a mosaic patient in which we detected the DUX4-fl
transcript in both short- and long-allele cells (Supplemen-
tary Figure S9A,B). We also detected an increased expres-
sion ofDUX4 target genes in these samples (Supplementary
Figure S9C). Additionally, the pathogenic DUX4-fl tran-
script is produced in different hiPSC clones derived from
FSHD2 patients but also from BAMS cells with disparities
in the level of expression between samples, regardless of the
type of disease (Figure 6E, F). Sequences of the different
transcripts are identical and match the DUX4-fl sequence
containing exons 1–3 (not shown).
The PAS sequence, a degenerated polyadenylation site
(AUUAAA) described as the main poly(A) site in FSHD
muscle cells and required for stabilization of the DUX4
pathogenic transcript is located 766 bp downstream of
the DUX4 stop codon (Figure 6D). We characterized the
DUX4-fl transcript produced in the different cell types to
test whether different transcripts are produced in BAMS or
FSHD cells. To this aim, we performed a 3′ RACE assay
and sequenced the DUX4-fl 3′ UTR (Supplementary Fig-
ure S10). We confirmed production of the DUX4-fl tran-
script in the three FSHD2 patients and one out the three
BAMS cases tested and showed that the sequence of the
3′ UTR is identical in the two pathologies (Supplementary
Figure S10). We inferred from these results that the DUX4-
fl pathogenic transcript is produced both in FSHD and
BAMS cells and that BAMS cells are permissive for pro-
duction of the DUX4-fl transcript implicated in FSHD.
Since bothBAMSandFSHDcells expressDUX4 (Figure
6E, F), we further assessed expression of different DUX4
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Figure 6. BAMS patients express the pathogenic DUX4-fl transcript and DUX4 targets. (A) Schematic representation of the SMCHD1 protein and
position of mutations in BAMS (cyan) or FSHD2 patients (red). BAMS-1 (E136G) and BAMS-2 (S135C) carry missense mutations in the ATPase domain
reported as gain of function. BAMS-9 carries a missense mutation in the C-terminal region of the extended GHKL-like ATPase domain (D420V). FSHD2
patient #14586 also carries a mutation in the ATPase domain (Q193P) while FSHD2-11440 and FSHD2-11491 carry a truncating mutation (p.S754* and
p.V1826Gfs* respectively). (B) In vitro analysis of ATPase activity using a recombinant wild-type extended SMCHD1 ATPase domain and a recombinant
extended SMCHD1 ATPase domain containing the FSHD2 Q193P mutation. Each graph shows ATP concentration (x axis, M) versus concentration
of ADP produced (y axis, M) for different concentrations of recombinant protein. The protein concentration is indicated in the inset legend adjacent
to the y axis. Means ± S.D. are shown for triplicate measurements. (C) Chromatin Immunoprecipitation assay for SMCHD1 in hiPSCs. Histogram bars
correspond to quantification of SMCHD1 binding to D4Z4 by digital droplet PCR after SMCHD1 immunoprecipitation. Enrichment was determined
by comparison to histone H3 immunoprecipitation with error bars corresponding to S.D. (D) Schematic representation of chromosome 4 and 4q35 locus
with position of the DUX4 coding sequence. Each D4Z4 monomer contains the first exon of the DUX4 ORF. The second and third exons correspond to
the 3′ untranslated region (3′ UTR). The third exon contains a non-canonical polyadenylation signal (PAS; TAATTT). Alternative splicing involving exon
1 (with or without exon 2) and downstream exons 3 to 7 give rise to different transcripts produced in the germline and stabilized by a polyadenylation
site downstream of exon 7. Transcripts consisting of exons 1–3 encode the DUX4-fl long isoform produced in FSHD cells and stabilized by the presence
of the PAS (20,40). This transcript is also detectable in healthy individuals (41,57,58). The DUX4-fl transcript is detectable using a nested PCR designed
to amplify transcripts containing the 3′ end of exon 1 and exon 3 containing the polyadenylation site. Position of primers is indicated by arrows. (E) We
evaluated expression of the DUX4-fl transcript in different hiPSCs clones derived from 2 clones from healthy donors (AG08; AG09; blue), three patients
with BAMS (BAMS-1; BAMS-2; BAMS-9, cyan); three patients with FSHD2 (11440; 11491; 14586, red), and two clones from FSHD1 patients (TalF
carrying two D4Z4 units; 12759 carrying 7 D4Z4 units, gray). Expression level was normalized to three different housekeeping genes (HKG). (F) DUX4
transcripts were analyzed by RT-PCR using primers designed to amplify the short isoform (DUX4-s), detectable in all cells and the DUX4-fl pathogenic
transcript. We detected the DUX4-fl transcript in samples 5, 6 (two clones derived from BAMS 9), 8 (BAMS 1), 10 (FSHD2, 11440), 12 (FSHD2, 14586)
and 14 (TalF; FSHD1 patient with two RU).
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target genes (ZSCAN4, MBD3L2 and TRIM43) as well
as expression of the TRIM28 gene required for DUX4
transcriptional activation (Supplementary Figure S11).
TRIM28 expression is not modulated in the different sets
of samples (Supplementary Figure S11E) but we noticed
increased expression of ZSCAN4, MBD3L2 and TRIM43
with no notable difference between BAMS, FSHD2 and
FSHD1 hiPSCs (Supplementary Figure S11A). Further-
more, DUX4-fl and DUX4 target genes are also detectable
in embryoid bodies at day 14 of differentiation for the three
groups of patients suggesting thatDUX4 remains expressed
at early differentiation stages in the two pathologies (Sup-
plementary Figure S11 B–D).
Altogether, these results show that DUX4 expression is
not only activated in FSHD1 and 2 cells but also in BAMS.
In both diseases, the DUX4-fl transcript is identical to the
pathogenic transcript described in FSHD muscle including
in its 3′ UTR indicating that BAMS cells are also permis-
sive forDUX4 expression.Furthermore, in FSHD1 hiPSCs,
production of this transcript is not correlated with a de-
creased D4Z4 methylation.
SMCHD1 is required for de novo methylation of the D4Z4
repeat
To further investigate the role of SMCHD1 in DNAmethy-
lation, we analyzed the distribution of methylated CGs in
somatic cancer cells inwhichSMCHD1 has been deleted us-
ing a zinc finger nuclease (HCT116-SMCHD1KO) in com-
parisonwith cells where the de novoDNAmethyltransferase
(DNMT) 3B (3B KO) is deleted or in cells were both the
maintenance enzyme DNMT1 and DNMT3B (dKO cells)
are absent (Figure 7A, Supplementary Figure S12, Supple-
mentary Table S2). D4Z4 methylation is strongly decreased
in dKO cells but not affected in DNMT3B-KO cells as pre-
viously observed (41).More strikingly, D4Z4methylation is
not decreased in SMCHD1-KOHCT116 cells compared to
the parental HCT116 cell line (Figure 7A, Supplementary
Table S2). This absence of effect is not cell-type dependent
because similar results were observed in HEK293 cells in
which SMCHD1 has been invalidated the same way (Fig-
ure 7B, Supplementary Figure S12B, Supplementary Table
S2). These data strongly suggest that when theD4Z4methy-
lation pattern is established, SMCHD1 is not required for
DNA methylation maintenance. In agreement with a role
for SMCHD1 in the epigenetic regulation of D4Z4, this
factor binds the proximal part of the macrosatellite where
most methylation change occurs and highly enriched in the
H3K9me3 heterochromatin mark (Figure 7C). Moreover,
as observed for DNA methylation, SMCHD1 invalidation
does not lead to a massive loss in this repressive H3K9me3
histone mark (Figure 7C). We further showed that in the
HCT116 cells carrying a 4qA-type allele and thus permis-
sive for DUX4 activation (supplementary Figure S12C,D),
invalidation of both DNMTs or SMCHD1 leads to tran-
scription of theDUX4 retrogene encoded by themacrosatel-
lite and production of the DUX4 long transcript (DUX4-fl)
(Supplementary Figure S12E,F).
As observed in hiPSCs from FSHD1 patients, SM-
CHD1 inactivation in somatic cells induces expression of
theDUX4-fl retrogene without a massive hypomethylation.
Altogether, this suggest a role for SMCHD1 in the regula-
tion of DUX4 expression independent of D4Z4 chromatin
status as observed for other loci upon acute Smchd1 dele-
tion in mice (8).
DISCUSSION
To investigate the epigenetic mechanisms linked to SM-
CHD1 mutations in two rare diseases, FSHD2 and BAMS
(28,29), we reprogrammed primary fibroblasts from pa-
tients affected with these diseases. We also included hiP-
SCs clones from classical type 1 FSHD using cells from pa-
tients with differing numbers of D4Z4 units. In the differ-
ent contexts, we analyzed DNA methylation of the D4Z4
macrosatellite linked to FSHD and of other repetitive el-
ements in patients’ primary fibroblasts, hiPSCs after re-
programming or human stem cells (FSHD1 and healthy
donors) after sodium bisulfite treatment of genomic DNA
and deep-sequencing.
We observed that upon reprogramming, D4Z4 methy-
lation increases in FSHD1 to a level similar to control
cells. Interestingly, the FSHD1-hiPSCs methylation profile
is highly similar to that of hESCs (FSHD1 and controls).
Given this high methylation in pluripotent cells, we con-
cluded that D4Z4 methylation level does not necessarily
correlate with the number of residual repeats but is a fea-
ture of stemness. These observations further suggest that
D4Z4 is dynamically remethylated upon reprogramming.
We confirmed this hypothesis in individual clones derived
from a mosaic patient and a time course analysis show-
ing that D4Z4 remethylation follows acquisition of pluripo-
tency. InFSHD2patients carrying amutation inSMCHD1,
D4Z4 methylation is low in primary fibroblasts and slightly
increases upon reprogramming while methylation increases
more in BAMS hiPSCs. These results together with the
absence of methylation changes in SMCHD1-deficient so-
matic cells emphasize a role for this protein in the de novo
methylation of the macrosatellite. Hence, different muta-
tions in this gene have different consequences on the epige-
netic regulation of D4Z4 but not on its transcription as ev-
idenced by the production of the DUX4-fl pathogenic tran-
script in both FSHD and BAMS patient’s cells.
FSHD is associatedwith production of theDUX4-fl tran-
script transcribed from the last D4Z4 unit and adjacent
4qA and pLAM sequences containing a polyadenylation
site (PAS) required for stabilization of the transcript and
production of the DUX4 protein (20). In FSHD patients,
DUX4 accumulation in 1 out of 1000 cells has been pro-
posed as sufficient to generate toxicity in the muscle, by
activating a number of target genes of unknown function
in muscle biology (27). We detected expression of the long
pathogenic DUX4 transcript (DUX4-fl) able to encode the
DUX4 protein thanks to the presence of a polyadenyla-
tion site in FSHD and BAMS cells as well as some of
the DUX4 target genes such as ZSCAN4, TRIM43 or
MBD3L2 to a level comparable between samples. Thus,
BAMS patients’ cells are permissive for DUX4 transcrip-
tion. However, BAMS patients do not develop muscular
dystrophy while SMCHD1 mutations in FSHD2 are not
associated with craniofacial defects as in BAMS (29). The
same holds true for patients with deletion of the 18p11.32
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Figure 7. Invalidation of SMCHD1 in somatic cells does not lead toD4Z4 hypomethylation. (A)We determinedD4Z4methylation in the HCT116 cell line
(HCT116), and in clones in whichDNMT3B (3BKO), bothDNMT1 andDNMT3B (dKO) or SMCHD1 (SMCHD1-KO) have been invalidated using Zinc
finger nucleases. DNAmethylation was analyzed after sodium bisulfite modification and deep-sequencing for four regions across D4Z4. The percentage of
methylation was calculated for each individual CpG, black bars correspond to methylated CGs; white bars to unmethylated ones. Methylation percentages
are provided in the Supplementary Table S2 as the average values± S.D from three independent experiments. (B) D4Z4methylation in theHEK293 cell line
and in HEK cells invalidated for SMCHD1 for four regions across D4Z4. (C) Schematic representation of D4Z4 from position 1 to 3303 relative to the two
flanking KpnI sites and position of primers used for ChIP-qPCR. We analyzed SMCHD1 binding and distribution of H3K9 trimethylation across D4Z4
after chromatin immunoprecipitation in HCT116, dKO or SMCHD1-KO cells. Enrichment over input was determined by qPCR. Histograms display the
average enrichment after normalization over a single copy intergenic region. Values are average from at least three independent biological replicates and a
technical duplicate. Error bar represents standard error. Statistical significance was determined using a paired two-tailed Student’s t test (*P< 0.01; **P<
0.001; ***P < 0.0001).
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region encompassing the SMCHD1 gene showing amarked
D4Z4 hypomethylation. Based on the estimation of qA-
type haplotype frequency in the Caucasian population (42)
required forDUX4-fl production, 12.6% of the 18p deletion
patients would be permissive forDUX4 transcription and at
risk of developing FSHD (42) but do not present this mus-
cular dystrophy (43).
Our results thus raise important questions on the impact
of D4Z4 hypomethylation, chromatin relaxation, the spe-
cific role of DUX4 in the FSHD pathogenesis and the rel-
evance of targeting of SMCHD1 or DUX4 for the devel-
opment of therapeutics. Along the same line, the DUX4
transcription factor activated at the two-cell stage in the
mouse and four-cell stage in human embryos is required
the Zygotic Genome Activation stage (ZGA) (44–46). This
suggests that production of this transcription factor in em-
bryonic stem cells does not depend on the presence of the
pLAM sequence and that both qA and qB alleles which are
equally common in the population (19), are permissive for
DUX4 transcription and production of the DUX4 protein.
If the qB allele is unable to support the production of a
stable DUX4 protein, individuals carrying two qB alleles
should not proceed past the 8-cell stage.
Several DUX4 transcripts have been described, with a
germline-specific isoform containing additional exons (ex-
ons 4–7) encoding the 3′ UTR. These different isoforms are
translated into the same protein encoded by theDUX4ORF
contained within exon 1 of the last D4Z4 repeat (20,40).
This raise novel questions on the regulation of splicing of
this key transcription factor in healthy versus pathological
contexts.
During reprogramming, DNA methylation patterns are
not fully erased as in early embryogenesis, but involve
profound epigenetic changes and acquisition of an epige-
netic profile similar to embryonic stem cells. Hence, repro-
grammed cells often keep memory of the epigenetic pat-
tern of the parental somatic cells used for reprogramming
but also acquire iPSC-specific DNA methylation profiles
(47,48). The consistent increase in D4Z4 methylation in
control and FSHD1 hiPSCs and the comparison with other
repetitive sequences, including the TAR1 subtelomeric re-
peats shows that D4Z4 does not retain the methylation pat-
tern inherited from the donor cells but acquires a methy-
lation profile identical to ESCs and thus likely specific to
cell stemness. Our results strongly suggest a role for SM-
CHD1 in this remethylation. D4Z4 methylation is high in
human ES cells, which are derived from the inner blasto-
cyst cell mass (ICM), a later developmental stage compared
to ZGA. Interestingly, SMCHD1 expression peaks at the
8-cell stage in human embryos (49), a stage corresponding
to the silencing of DUX4 (50–52), suggesting a role for this
factor in the remethylation of the repeat at early embry-
onic stages after post-fertilization waves of zygotic genome
demethylation.
The high D4Z4 methylation level in FSHD1 hESCs or
hiPSCs and decreased methylation in somatic cells fur-
ther suggests that acquisition of this epigenetic mark in
pluripotent cells is followed by demethylation in somatic
cells (24,31,33) opening new questions on the molecular
mechanisms enabling this process. Methylation of repeti-
tive elements, in particular at early developmental stages,
is regulated by specific pathways. This methylation is re-
quired to maintain a high level of chromatin compaction
and limit genomic instability especially at regions proximal
to centromeres or telomeres enriched in theH3K9me3 hete-
rochromatin marks, which are more resistant to the erasure
of inherited marks. In normal cells, D4Z4 is highly enriched
in H3K9me3 and it remains to be determined whether per-
sistence of this mark acts as a signal that facilitates remethy-
lation of the underlying DNA. Interestingly, the absence of
remethylation in FSHD2 is reminiscent of what is observed
in cells from ICF1 patients (Immunodeficiency, centromeric
instability and facial abnormalities, OMIM #242860) car-
rying mutations in the de novo DNA methyltransferase 3B
(DNMT3B) gene (35) suggesting common pathways. Loss
of Smchd1 causes defective X chromosome silencing (1,53)
andXi topological changes (8,54). FSHD2 or BAMSmuta-
tions do not affect X inactivation and biochemical analyses
revealed that depending on the type of mutation, the im-
pact on the function of the protein is different with a gain
of ATPase activity in most BAMS patients and a loss of
function in FSHD2 (29,30). By comparing patients with dif-
ferent mutations in the ATPase domain, we show that this
domain might be involved in the loading or release from
DNA while gain-, loss-of-function are all associated with
D4Z4 hypomethylation.
Overall, our results unravel a role for SMCHD1 in the
regulation ofD4Z4methylation in pluripotent cells but sug-
gest that SMCHD1 might be dispensable for maintaining
DNAmethylation in somatic cells. As observed for the AT-
Pase activity (29,30) and consistent with previous results
(8), our results also indicate that depending on the type of
mutation, the binding of SMCHD1 to chromatin might be
different. This opens new perspectives to monitor the im-
pact of SMCHD1 on chromatin regulation but also for un-
derstanding the respective involvement of SMCHD1 mu-
tations in FSHD2 or BAMS. Pluripotent cells thus appear
as a potent model for studying the dynamic regulation of
D4Z4 methylation, the role of SMCHD1, FSHD patho-
genesis and associated epigenetic mechanisms. Given the
high level of methylation in the FSHD1-hESCs and the de-
creased methylation in somatic tissues, our results raise in-
teresting questions on the regulation and dynamics of DNA
methylation at repetitive sequences, corresponding to the
largest fraction of the human genome (55). Our findings
also force the revisiting of a number of previously proposed
concepts regarding D4Z4 methylation in FSHD and open
new avenues for investigating the molecular defects leading
to muscle alterations, including in the regulation of DUX4
especially at early differentiation stages.
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